Amer Renal Assoc Financials

Amer Renal Stock Summary

Amer Renal competes with Alvotech, Cytek Biosciences, Teleflex Incorporated, Albemarle Corp, and Hawkins. American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. The company was founded in 1999 and is headquartered in Beverly, Massachusetts. American Renal operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 4977 people.

Amer Renal Key Financial Ratios

Generally speaking, Amer Renal's financial ratios allow both analysts and investors to convert raw data from Amer Renal's financial statements into concise, actionable information that can be used to evaluate the performance of Amer Renal over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Amer Renal Assoc reports annually and quarterly.

Amer Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Amer Renal's current stock value. Our valuation model uses many indicators to compare Amer Renal value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amer Renal competition to find correlations between indicators driving Amer Renal's intrinsic value. More Info.Amer Renal Assoc is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies reporting about  0.25  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Amer Renal Assoc is roughly  4.03 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Amer Renal by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Amer Renal's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amer Renal's earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

If you are still planning to invest in Amer Renal Assoc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Renal's history and understand the potential risks before investing.